Paper25973333
Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy.
Velikyan I and 6 others. Am J Nucl Med Mol Imaging, 2015. Cited by 24 papers, by iCite.
Cite this record
ConductScience Library. Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy. Papers, record 25973333. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25973333
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15653658 | Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. | J Nucl Med | 2005 | https://conductscience.org/library/papers/15653658 | PubMed |
| 2 | 11340564 | [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. | Int J Cancer | 2001 | https://conductscience.org/library/papers/11340564 | PubMed |
| 3 | 9044843 | Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. | Cancer Res | 1997 | https://conductscience.org/library/papers/9044843 | PubMed |
| 4 | 21711223 | Positron emitting [68Ga]Ga-based imaging agents: chemistry and diversity. | Med Chem | 2011 | https://conductscience.org/library/papers/21711223 | PubMed |
| 5 | 8455089 | Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. | J Nucl Med | 1993 | https://conductscience.org/library/papers/8455089 | PubMed |
| 6 | 22388631 | Lutetium-labelled peptides for therapy of neuroendocrine tumours. | Eur J Nucl Med Mol Imaging | 2012 | https://conductscience.org/library/papers/22388631 | PubMed |
| 7 | 11585290 | [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. | Eur J Nucl Med | 2001 | https://conductscience.org/library/papers/11585290 | PubMed |
| 8 | 16025254 | Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. | Diabetologia | 2005 | https://conductscience.org/library/papers/16025254 | PubMed |
| 9 | 12236780 | Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody. | Bioconjug Chem | 2002 | https://conductscience.org/library/papers/12236780 | PubMed |
| 10 | 16447056 | Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. | Diabetologia | 2006 | https://conductscience.org/library/papers/16447056 | PubMed |
| 11 | 19585115 | Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours. | Eur J Nucl Med Mol Imaging | 2009 | https://conductscience.org/library/papers/19585115 | PubMed |
| 12 | 19915842 | Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. | Eur J Nucl Med Mol Imaging | 2010 | https://conductscience.org/library/papers/19915842 | PubMed |
| 13 | 17575235 | [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17575235 | PubMed |
| 14 | 19383333 | Imaging and cancer: a review. | Mol Oncol | 2008 | https://conductscience.org/library/papers/19383333 | PubMed |
| 15 | 18445841 | Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18445841 | PubMed |
| 16 | 21555692 | Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21555692 | PubMed |
| 17 | 24857864 | Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma. | Nucl Med Biol | 2014 | https://conductscience.org/library/papers/24857864 | PubMed |
| 18 | 11190491 | Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model. | Cancer Biother Radiopharm | 2000 | https://conductscience.org/library/papers/11190491 | PubMed |
| 19 | 23223392 | Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. | J Nucl Med | 2013 | https://conductscience.org/library/papers/23223392 | PubMed |
| 20 | 22768026 | Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma. | Theranostics | 2012 | https://conductscience.org/library/papers/22768026 | PubMed |
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38708210 | Nanoassembly-Mediated Exendin-4 Derivatives to Decrease Renal Retention. | ACS Omega | 2024 | https://conductscience.org/library/papers/38708210 | PubMed |
| 38195680 | Carrier systems of radiopharmaceuticals and the application in cancer therapy. | Cell Death Discov | 2024 | https://conductscience.org/library/papers/38195680 | PubMed |
| 37265006 | New Radiolabeled Exendin Analogues Show Reduced Renal Retention. | Mol Pharm | 2023 | https://conductscience.org/library/papers/37265006 | PubMed |
| 37242457 | Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37242457 | PubMed |
| 37109517 | Role of Exendin-4 Functional Imaging in Diagnosis of Insulinoma: A Systematic Review. | Life (Basel) | 2023 | https://conductscience.org/library/papers/37109517 | PubMed |
| 36431313 | Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update. | J Clin Med | 2022 | https://conductscience.org/library/papers/36431313 | PubMed |
| 35762648 | Multivalent γ-PGA-Exendin-4 Conjugates to Target Pancreatic β-Cells. | Chembiochem | 2022 | https://conductscience.org/library/papers/35762648 | PubMed |
| 35056858 | Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [68Ga]Ga-NODAGA-Exendin-4 Produced by a Fully Automated Method. | Molecules | 2022 | https://conductscience.org/library/papers/35056858 | PubMed |
| 33297381 | Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors. | Diagnostics (Basel) | 2020 | https://conductscience.org/library/papers/33297381 | PubMed |
| 33019671 | Beta Cell Imaging-From Pre-Clinical Validation to First in Man Testing. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33019671 | PubMed |
| 31903131 | Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics. | Theranostics | 2020 | https://conductscience.org/library/papers/31903131 | PubMed |
| 29335487 | Increased Expression of GLP-1R in Proliferating Islets of Men1 Mice is Detectable by [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 /PET. | Sci Rep | 2018 | https://conductscience.org/library/papers/29335487 | PubMed |
| 28891030 | Species differences in pancreatic binding of DO3A-VS-Cys40-Exendin4. | Acta Diabetol | 2017 | https://conductscience.org/library/papers/28891030 | PubMed |
| 28721305 | Fully automated GMP production of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 for clinical use. | Am J Nucl Med Mol Imaging | 2017 | https://conductscience.org/library/papers/28721305 | PubMed |
| 28295000 | Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms. | Pharmaceuticals (Basel) | 2017 | https://conductscience.org/library/papers/28295000 | PubMed |
| 28067253 | Whole organ and islet of Langerhans dosimetry for calculation of absorbed doses resulting from imaging with radiolabeled exendin. | Sci Rep | 2017 | https://conductscience.org/library/papers/28067253 | PubMed |
| 28025655 | Targets and probes for non-invasive imaging of β-cells. | Eur J Nucl Med Mol Imaging | 2017 | https://conductscience.org/library/papers/28025655 | PubMed |
| 27819034 | Quantification of β-Cell Mass in Intramuscular Islet Grafts Using Radiolabeled Exendin-4. | Transplant Direct | 2016 | https://conductscience.org/library/papers/27819034 | PubMed |
| 27275825 | Feasibility of Multiple Examinations Using (68)Ga-Labelled Collagelin Analogues: Organ Distribution in Rat for Extrapolation to Human Organ and Whole-Body Radiation Dosimetry. | Pharmaceuticals (Basel) | 2016 | https://conductscience.org/library/papers/27275825 | PubMed |
| 27094935 | In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use. | Diabetologia | 2016 | https://conductscience.org/library/papers/27094935 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25973333
GET https://conductscience.org/api/papers/v1/25973333/references?page=2